AI Earnings Predictions for SS Innovations International Inc. (SSII)

EX-99.1

2 ea030188701ex99-1.htm

PRESS RELEASE, DATED AUGUST 13, 2026

Exhibit 99.1

SS Innovations Reports Second Quarter 2026 Financial Results

Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales

FORT LAUDERDALE, FLA – August 13, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and six months ended June 30, 2026. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, with the Securities and Exchange Commission on August 13, 2026.

Second Quarter 2026 Overview

●Revenue increased 39.4% to $13.9 million from $10.0 million in the second quarter of 2025.

●Gross margin equaled 50.9%, compared to 59.1% in the second quarter of 2025.

●Gross profit rose 20.0% to $7.1 million from $5.9 million in the second quarter of 2025.

●Net loss of $2.7 million, or $(0.01) per diluted share, compared to a net loss of $0.3 million, or $(0.00) per diluted share, in the second quarter of 2025.

●SSi Mantra surgical robotic system installations totaled 30, up 30.4% from 23 installations in the second quarter of 2025.

First Half 2026 Overview

●Revenue increased 65.6% to $25.0 million from $15.1 million in the first half of 2025.

●Gross margin expanded to 49.6% from 46.3% in the first half of 2025.

●Gross profit rose 77.5% to $12.4 million from $7.0 million in the first half of 2025.

●Net loss of $6.2 million, or $(0.03) per diluted share, compared to a net loss of $5.9 million, or $(0.03) per diluted share, in the first half of 2025.

●SSi Mantra surgical robotic system installations totaled 56, up 47.4% from 38 installations in the first half of 2025.

As of June 30, 2026

●Long-term debt of $0.

●Cash and cash equivalents totaled $13.6 million, excluding restricted cash.

●SSi Mantra cumulative installed base totaled 224 systems across twelve countries and cumulative surgeries reached 12,272, including 175 telesurgeries, 637 cardiac procedures and 222 pediatric surgeries.

CEO Commentary

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “SS Innovations delivered record quarterly revenue of $13.9 million in the second quarter of 2026, up 39% year over year, reflecting strong adoption of our advanced SSi Mantra surgical robotic system by leading hospitals and surgeons in India and abroad. We continue to expand awareness of the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency. Recently the SSi Mantra has been showcased in several high-profile international long-distance telesurgeries as well as at this year’s Global Multi-Specialty Robotic Surgery Conference in New Delhi, which we hosted, and the 2026 Society of Robotic Surgery Annual Meeting in Florida. We appreciate the widespread positive reception of the SSi Mantra at these events and were excited to win the ‘Outstanding Company’ category at the 2026 Surgical Robotics Industry Awards in June.”

Dr. Srivastava continued, “We remain enthusiastic about our ability to lead our foundational market of India, which is immense and growing, while expanding our global footprint in underserved countries and aiming for entry into the United States and European Union. We expect the U.S. Food and Drug Administration to complete its review of our 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can obtain by the end of 2026. Our SSI Mantra has been engineered for precision, built to perform, and created to democratize access to advanced surgical robotic care—all underpinning our confidence in the future.”

Select Business Highlights in Second Quarter 2026

●In April 2026, the Company hosted the Global Multi-Specialty Robotic Surgery Conference in New Delhi, India, bringing together distinguished surgeons, global thought leaders and prominent innovators to discuss and shape the future of robotic and minimally invasive surgery. The event drew more than 1,600 attendees and 1,800 virtual participants from 19 nations.

●On May 7, 2026, the Company announced the successful completion of a landmark telesurgery performed in Perth, Australia, more than 4,500 miles from the patient in India, utilizing the SSi Mantra surgical robotic system (the “SSi Mantra”) and the SSi MantrAsana tele-surgeon console.

●On June 4, 2026, the Company announced the successful completion of a robotic-assisted heart procedure performed with the SSi Mantra across approximately 12,500 miles (20,000 kilometers) of fiber network distance between Guyana and India, making it the world’s then longest-di

EX-99.1

2 ea029045301ex99-1.htm

PRESS RELEASE, DATED MAY 13, 2026

Exhibit 99.1

SS Innovations Reports First Quarter 2026 Financial Results

Record quarterly revenue driven by strong growth in SSi Mantra installations and procedures

Fort Lauderdale, FL – May 13, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2026. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, with the Securities and Exchange Commission on May 13, 2026.

First Quarter 2026 Overview

●Revenue increased 116.8% to $11.1 million from $5.1 million in the first quarter of 2025.

●Gross margin expanded to 48.0% from 21.2% in the first quarter of 2025.

●Gross profit rose 390.0% to $5.3 million from $1.1 million in the first quarter of 2025.

●Net loss of $3.6 million, or $(0.02) per diluted share, compared to a net loss of $5.7 million, or $(0.03) per diluted share, in the first quarter of 2025.

●SSi Mantra surgical robotic system installations totaled 26, up 73.3% from 15 installations in the first quarter of 2025.

As of March 31, 2026

●Long-term debt of $0.

●Cash and cash equivalents totaled $16.0 million, excluding restricted cash.

●SSi Mantra cumulative installed base totaled 194 across eleven countries and cumulative surgeries reached 9,744, including 157 telesurgeries, 482 cardiac procedures and 161 pediatric surgeries.

CEO Commentary

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “In the first quarter of 2026 we reported record quarterly revenue of $11.1 million, up 117% year over year, driven by robust growth in SSi Mantra installations and procedures. Strong adoption by hospitals and physicians reflects the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency. Among other developments in the quarter, we received regulatory approval for the SSi Mantra for multiple indications in Sri Lanka and Kenya and for telesurgery in Indonesia and the Philippines. We also successfully completed a private placement in March 2026 that provided SS Innovations with approximately $18.6 million in gross proceeds to fuel growth initiatives.”

Dr. Srivastava continued, “Looking ahead, we aim to fortify our position as a leader in the substantial Indian market, expand our global footprint in underserved countries, and secure entry into the United States and European Union markets. We expect the U.S. Food and Drug Administration to complete its review of our 510(k) premarket notification for the SSi Mantra this year. Separately, we continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can also obtain in 2026. We are very excited about the growth runway ahead and remain steadfast in our commitment to democratizing access to advanced surgical robotic care.”

Select Business Highlights in First Quarter 2025

●In January 2026, the Company received regulatory approval for the SSi Mantra from the National Medicines Regulatory Authority (“NMRA”) in Sri Lanka and from the Pharmacy and Poisons Board (“PPB”) in Kenya.

●On March 9, 2026, the Company announced the completion of a private placement of its common stock, generating approximately $18.6 million in gross proceeds before deducting offering expenses, to support growth initiatives. In the offering, the Company offered and sold a total of 5,774,839 shares of common stock consisting of: an aggregate of 1,300,006 shares of common stock at an average price of $4.00 per share to certain of the Company’s directors and executive officers, or a total of approximately $5.2 million; and an aggregate of 4,474,833 shares of common stock at $3.00 per share, or approximately $13.4 million cumulatively, to non-affiliate investors.

●On March 18, 2026, the Company announced that the SSi Mantra surgical robotic system received approval for telesurgeries in Indonesia and the Philippines.

Revenue Breakdown and Summary of Installations / Surgeries

Category

Q1 2025

Q1 2026

Variance Percentage

System sales $4,502,482 $9,575,370 $5,072,888 112.7%

Instrument sales 477,208 1,151,228 674,020 141.2%

Warranty sales 122,504 357,686 235,182 192.0%

Lease income 18,416 17,082 (1,334) (7.2)%

Total revenue $5,120,610 $11,101,366 $5,980,756 116.8%

SSi Mantra installations 15 26 11 73.3%

Cumulative installed base1 78 194 116 148.7%

SSi Mantra surgeries 787 1,859 1,072 136.2%

Cumulative surgeries1 3,568 9,744 6,176 173.1%

1at period end

2

About SS Innovations

SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery a

EX-99.1

2 ea028066501ex99-1.htm

PRESS RELEASE, DATED MARCH 10, 2026

Exhibit 99.1

SS Innovations Reports Fourth Quarter and Full Year 2025 Financial Results

Strong growth in SSi Mantra installations, procedures and revenues

Fort Lauderdale, FL – March 10, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and twelve months ended December 31, 2025. The Company also filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the Securities and Exchange Commission on March 10, 2026.

Fourth Quarter 2025 Overview

●Revenue increased 79.1% to $14.5 million from $8.1 million in the fourth quarter of 2024.

●Gross margin of 43.9% compared to 48.9% in the fourth quarter of 2024.

●Gross profit rose 60.7% to $6.4 million from $4.0 million in the fourth quarter of 2024.

●Net loss of $2.5 million, or $(0.01) per diluted share, compared to a net loss of $1.9 million, or $(0.01) per diluted share, in the fourth quarter of 2024.

●SSi Mantra surgical robotic system installations totaled 40, up 81.8% from 22 installations in the fourth quarter of 2024 and up 48.1% from 27 installations in the third quarter of 2025.

Full Year 2025 Overview

●Revenue increased 105.7% to $42.5 million from $20.6 million in 2024.

●Gross margin expanded to 46.0% from 40.9% in 2024.

●Gross profit rose 131.2% to $19.5 million from $8.5 million in 2024.

●Net loss of $12.1 million, or $(0.06) per diluted share, compared to net loss of $19.2 million, or $(0.11) per diluted share, in 2024.

●SSi Mantra surgical robotic system installations totaled 103, up 119.1% from 47 installations in 2024.

As of December 31, 2025

●Long-term debt of $0.

●Cash and cash equivalents totaled $3.2 million, excluding restricted cash.

●SSi Mantra cumulative installed base totaled 168 across ten countries and cumulative surgeries reached 7,885, including 120 telesurgeries, 390 cardiac procedures and 121 pediatric surgeries.

CEO Commentary

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “In the fourth quarter of 2025, we achieved strong growth in SSi Mantra installations, procedures and revenues, capping off a successful year for SS Innovations. Among our accomplishments in 2025, we gained significant share of the surgical robotics market in India, expanded into new global geographies, and progressed along the regulatory pathways required for entering the United States and European Union markets. We also continued to pioneer robotic telesurgery, attaining multiple new procedure milestones and unveiling cutting-edge innovations such as the Tele Surgeon Console and MantraM mobile robotic telesurgery unit. Finally, the uplisting of our shares to Nasdaq has enhanced market awareness of our growth story and expanded our audience of potential investors.”

Dr. Srivastava continued, “After quarter-end we completed a private placement of common stock, which brings us new long-term oriented institutional investors and approximately $18.6 million of gross proceeds aimed to fuel SS Innovations’ growth in 2026 and beyond. Significant insider participation in this financing reflects our strong confidence in SS Innovations’ future. We will continue to invest in enhancements to our advanced, cost-effective SSi Mantra surgical robotic system and expand our capacity to lead the vast Indian market, penetrate underserved global geographies, and prepare for our entry into the United States and European Union. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra by mid-2026. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can also obtain this year. In conclusion, we expect continuing strong growth in 2026 as we deploy the SSi Mantra in existing and new markets, increasing access to world-class surgical robotic care.”

Select Business Highlights in Fourth Quarter 2025

●On November 6, 2025, the Company announced the successful completion of the first telesurgery performed with the SSi Mantra Tele Surgeon Console.

●On December 5, 2025, the Company submitted a 510(k) premarket notification to the United States Food and Drug Administration (the “FDA”) for the SSi Mantra surgical robotic system, covering multiple indications including general, urological, colorectal, gynecological and cardiac surgeries.

Subsequent Events

●On January 6, 2026, the Company announced the development of five new 5-millimeter surgical instruments for clinical use across multiple specialties, including pediatric, cardiac, and head and neck surgery, among other procedures involving smaller anatomical structures.

●On March 9, 2026, the

EX-99.1

2 ea027262901ex99-1_ssinno.htm

PRESS RELEASE, DATED JANUARY 13, 2026

Exhibit 99.1

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

Anticipated strong revenue growth driven by higher unit sales of SSi Mantra surgical robotic system

Fort Lauderdale, FL – January 13, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced preliminary unaudited revenue and other select operating metrics for the three and twelve months ended December 31, 2025.

For the fourth quarter of 2025, the Company expects to report:

●Revenue of approximately $15.0 million, up 85% from revenue of $8.1 million in the fourth quarter of 2024.

●SSi Mantra installations of 37, up 68% from 22 installations in the fourth quarter of 2024.

For the full year 2025, the Company expects to report:

●Revenue of approximately $43.0 million, up 108% from revenue of $20.6 million in 2024.

●SSi Mantra installations of 103, up 119% from 47 installations in 2024.

The SSi Mantra cumulative installed base totaled 168 as of December 31, 2025, up 158% from 65 as of December 31, 2024.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We expect to report strong fourth quarter revenue growth, driven by higher unit sales of our advanced, cost-effective SSi Mantra surgical robotic system in India and abroad. We are committed to democratizing excellence in surgical care on a global scale, including in the United States and Europe. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra in the first half of 2026. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can obtain in the first half of 2026. We look forward to providing additional financial details when we release our fourth quarter financial results in the latter part of February.”

The Company expects to report its fourth quarter and full year 2025 financial results before the end of February.

The estimated financial and operating results in this press release are preliminary, unaudited and subject to completion, and may change as a result of management’s continued review. Such preliminary results are subject to the finalization of quarter-end financial and accounting procedures. As a result, investors should exercise caution in relying on this information and should not draw any inferences from this information. This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with GAAP and reviewed by our independent registered public accounting firm.

About SS Innovations

SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of robotic surgical procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra

The SSi Mantra surgical robotic system is a user-friendly,

modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.

Forward Looking Statements

This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements include all statements that are not historical statements of fact and statements regarding the Company’s

intent, belief or expectations, including, but not limited to, statements regarding the Company’s fourth

EX-99.1

2 ea026284701ex99-1_ssinnova.htm

PRESS RELEASE, DATED OCTOBER 28, 2025

Exhibit 99.1

SS Innovations Reports Third Quarter 2025 Financial Results

Quarterly Revenue Increased 192.5% Year over Year to $12.8 Million Driven by Higher SSi Mantra 3 Unit Sales

Fort Lauderdale, FL – October 28, 2025 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and nine months ended September 30, 2025. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, with the Securities and Exchange Commission on October 28, 2025.

Third Quarter 2025 Overview

●Revenue increased 192.5% to $12.8 million from $4.4 million in the third quarter of 2024.

●Gross margin of 48.1% compared to 52.8% in the third quarter of 2024.

●Gross profit rose 166.0% to $6.2 million from $2.3 million in the third quarter of 2024.

●Net loss of $3.7 million, or $(0.02) per diluted share, compared to a net loss of $3.2 million, or $(0.02) per diluted share, in the third quarter of 2024.

●SSi Mantra surgical robotic system installations totaled 27, up 350.0% from 6 installations in the third quarter of 2024 and up 17.4% from 23 installations in the second quarter of 2025.

First Nine Months 2025 Overview

●Revenue increased 123.0% to $28.0 million from $12.5 million in the first nine months of 2024.

●Gross margin expanded to 47.1% from 35.8% in the first nine months of 2024.

●Gross profit rose 193.7% to $13.2 million from $4.5 million in the first nine months of 2024.

●Net loss of $9.7 million, or $(0.05) per diluted share, compared to net loss of $17.2 million, or $(0.10) per diluted share, in the first nine months of 2024.

●SSi Mantra surgical robotic system installations totaled 63, up 152.0% from 25 installations in the first nine months of 2024.

As of September 30, 2025

●Long-term debt of $0.

●Cash and cash equivalents totaled $5.7 million, excluding restricted cash.

●SSi Mantra cumulative installed base totaled 127 in seven countries and cumulative surgeries reached 6,057, including 56 telesurgeries and 319 cardiac procedures.

CEO Commentary

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We delivered strong revenue growth in the third quarter of 2025, driven by higher unit sales of our advanced, cost-effective SSi Mantra 3 surgical robotic system in India and abroad. The SSi Mantra’s rapidly expanding installed base and increasing utilization reflect its cost advantages, ease of use, differentiated features, and compelling surgical outcomes.”

Dr. Srivastava continued, “We’ve become a leader in the large and growing India market and remain committed to democratizing access globally to cutting edge surgical robotic care. We now have regulatory approval for the SSi Mantra in seven countries and are taking steps to enter the U.S. and European Union markets. In September 2025, we successfully completed a human factors validation study at Johns Hopkins Hospital. This study will be an integral component of our upcoming 510(k) premarket notification, which we anticipate submitting to U.S. Food and Drug Administration (the “FDA”) in the fourth quarter of 2025. We also continue along the pathway towards a European Union CE marking certification in the first half of 2026. In conclusion, we are making good progress towards important regulatory milestones and remain well positioned for continuing robust organic growth in our existing markets.”

Select Business Highlights in Third Quarter 2025

●On September 9, 2025, the Company announced the successful completion of the first robotic telesurgery performed with the SSi Mantra surgical robotic system from the Mantra M mobile robotic telesurgery unit.

●On September 16, 2025, the Company announced the successful completion of the world’s first pediatric pyeloplasty telesurgery utilizing the SSi Mantra surgical robotic system.

●On September 26, 2025, the Company announced the appointment of Naveen Kumar Amar as Chief Financial Officer.

●In September 2025, the Company successfully completed a human factors validation study for the SSi Mantra at Johns Hopkins Hospital. This study will be a key component of the Company’s 510(k) premarket notification, which is expected to be submitted to the FDA in the fourth quarter of 2025.

Revenue Breakdown and Summary of Installations / Surgeries

Category

Q3 2024

Q3 2025

Variance Percentage

System sales $3,969,805 $11,705,375 $7,735,570 194.9%

Instrument sales 337,580 854,440 $516,860 153.1%

Warranty sales 58,547 244,399 $185,852 317.4%

Lease income 20,584 25,135 $4,551 22.1%

Total revenue $4,386,516 $12,829,349 $8,442,833 192.5%

SSi Mantra installations 6 27 21 350.0%

Cumulative installed base1 43 127 84 195.3%

SSi Mantr

EX-99.1

2 ea025215501ex99-1_ssinnov.htm

PRESS RELEASE, DATED AUGUST 7, 2025

Exhibit 99.1

SS Innovations Reports Second Quarter 2025 Financial Results

Record Quarterly Revenue of $10.0 Million Driven by Higher SSi Mantra 3 Unit Sales

Gross Profit More than Tripled, Driven by Gross Margin Expansion and Revenue Growth

Fort Lauderdale, FL – August 7, 2025 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and six months ended June 30, 2025. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, with the Securities and Exchange Commission on August 6, 2025.

Second Quarter 2025 Overview

●Revenue increased 121.8% to $10.0 million from $4.5 million in the second quarter of 2024.

●Gross margin expanded to 59.1% from 31.9% in the second quarter of 2024.

●Gross profit rose 311.4% to $5.9 million from $1.4 million in the second quarter of 2024.

●Net loss of $0.3 million, or $(0.00) per diluted share, compared to a net loss of $4.1 million, or $(0.02) per diluted share, in the second quarter of 2024.

●SSi Mantra surgical robotic system installations totaled 23, up 130% from 10 installations in the second quarter of 2024 and up 53% from 15 installations in the first quarter of 2025.

First Half 2025 Overview

●Revenue increased 85.6% to $15.1 million from $8.1 million in the first half of 2024.

●Gross margin expanded to 46.3% from 26.6% in the first half of 2024.

●Gross profit rose 223.3% to $7.0 million from $2.2 million in the first half of 2024.

●Net loss of $5.9 million, or $(0.03) per diluted share, compared to net loss of $14.0 million, or $(0.08) per diluted share, in the first half of 2024.

●SSi Mantra surgical robotic system installations totaled 38, up 100% from 19 installations in the first half of 2024.

As of June 30, 2025

●Long-term debt of $0.

●Cash and cash equivalents totaled $11.4 million, excluding restricted cash.

●SSi Mantra cumulative installed base totaled 105 in seven countries and cumulative surgeries reached 4,657.

CEO Commentary

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We continue to execute on our strategic initiatives and delivered strong revenue growth in the second quarter of 2025, driven by higher unit sales of our advanced, cost-effective SSi Mantra 3 surgical robotic system in India and abroad. Our second quarter gross profit more than tripled compared to the prior year quarter, reflecting higher revenue and significant gross margin expansion due to lower production costs, propelling a sharp narrowing in net loss to almost breakeven.”

Dr. Srivastava continued, “Our SSi Mantra 3 surgical robotic system continues to pioneer robotic telesurgery and cardiac procedures, achieving several ‘world firsts’ during and after the second quarter. We remain committed to democratizing excellence in surgical robotic care and SS Innovations’ uplisting to Nasdaq in April 2025 symbolizes a new chapter of global expansion. In that regard, based on recent FDA conversations, we now expect to submit a 510(k) application for multiple indications for the SSi Mantra 3 to the U.S. Food and Drug Administration by the end of September 2025—a potentially quicker pathway compared to the De Novo application we previously planned. We also continue along the pathway towards a European Union CE marking certification as soon as late 2025. Looking to the second half of the year, an expanding installed base combined with growing utilization of the SSi Mantra 3 positions us well for continuing robust organic growth.”

Select Business Highlights in Second Quarter 2025

●In April 2025, the Company’s common stock was listed for trading on The Nasdaq Stock Market LLC (“Nasdaq”).

●In June 2025, the Company rang the opening bell at the Nasdaq MarketSite in New York City.

●In June 2025, the Company’s SSi Mantra surgical robotic system performed its first robotic cardiac surgery in the Western Hemisphere.

Subsequent Events

●In July 2025, the world’s first robotic telesurgery for weight loss was performed utilizing the Company’s SSi Mantra 3 surgical robotic system.

●In July 2025, the world’s first intercontinental robotic cardiac telesurgery was performed (from France to India) utilizing the Company’s SSi Mantra 3 surgical robotic system.

●In July 2025, the first telesurgery in India’s public sector, which consists of more than 25,000 public hospitals, was performed utilizing the Company’s SSi Mantra 3 surgical robotic system.

●As of July 31, 2025, the SSi Mantra cumulative installed base totaled 112 systems and cumulative multi-specialty surgeries reached 5,038 without any device-related adverse events. This total included 40 telesurgeries and 273 cardiac procedures.

2

EX-99.1

2 ea024222901ex99-1_ssinnov.htm

PRESS RELEASE, DATED MAY 14, 2025

Exhibit 99.1

SS Innovations Reports First Quarter 2025 Financial Results

Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales

On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3

Fort Lauderdale, FL – May 14, 2025 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2025. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, with the Securities and Exchange Commission on May 14, 2025.

First Quarter 2025 Overview

●Revenue increased 40.8% to $5.1 million from $3.6 million in the first quarter of 2024.

●Gross margin expanded 121 basis points to 21.23% from 20.02% in the first quarter of 2024.

●Gross profit rose 49.3% to $1.1 million from $0.7 million in the first quarter of 2024.

●Net loss of $5.7 million, or $(0.03) per diluted share, compared to net loss of $9.8 million, or $(0.06) per diluted share, in the first quarter of 2024.

●SSi Mantra surgical robotic system installations totaled 15, up 66.7% from 9 installations in the first quarter of 2024.

As of March 31, 2025

●Long-term debt of $0.

●Cash and cash equivalents totaled $15.9 million, excluding restricted cash.

●SSi Mantra cumulative installed base totaled 78 and cumulative surgeries reached 3,568.

Subsequent Events

●On April 25, 2025, the Company’s common stock uplisted to The Nasdaq Capital Market®.

CEO Commentary

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “In the first quarter of 2025, we achieved record quarterly revenue of $5.1 million, up 40.8% from $3.6 million in the first quarter of 2024, driven by higher unit sales of our innovative, cutting-edge SSi Mantra 3 surgical robotic system to leading healthcare facilities in India and abroad. Our gross margin also improved during the quarter, primarily reflecting a reduction in raw material prices. With an expanding installed base and growing utilization of SSi Mantra 3 by medical professionals globally, SS Innovations is well positioned for continued robust organic growth during the remainder of the year.”

Dr. Srivastava continued, “After quarter end, we uplisted to Nasdaq, an exciting milestone that symbolizes a new chapter of global expansion for the Company. We intend to widen our presence beyond the seven countries where our SSi Mantra surgical robotic system has been cleared to market, with a focus on pursuing approval in the European Union and United States. We plan to submit a De Novo application for SSi Mantra to the U.S. Food and Drug Administration by the end of July 2025 for multiple indications and continue along the pathway towards a European Union CE Mark decision as soon as late 2025. Our vision is to decentralize and democratize robotic surgery by deploying our cost-effective, gold-standard SSi Mantra 3 devices across the globe for the benefit of a wider range of patients in need.”

Select Business Highlights in First Quarter 2025

●The SSi Mantra 3 surgical robotic system enabled the world’s first ever robotic cardiac telesurgery.

●The Company’s state-of-the-art mobile telesurgery unit debuted in India with the aim of improving remote surgical access.

●The SSi Mantra 3 received medical device regulatory approvals in the Philippines and Ukraine.

Revenue Breakdown and Summary of Installations / Surgeries

Category

Q1 2024

Q1 2025

Variance Percentage

System sales $3,494,759 $4,502,482 $1,007,723 28.8%

Instrument sales 118,515 477,208 358,693 302.7%

Warranty sales 9,407 122,504 113,097 1,202.3%

Lease income 15,012 18,416 3,404 22.7%

Total revenue $3,637,693 $5,120,610 $1,482,917 40.8%

SSi Mantra installations 9 15 6 67%

Cumulative installed base1 24 78 54 225%

SSi Mantra surgeries 361 787 426 118%

Cumulative surgeries1 981 3,568 2,587 264%

1at period end

About SS Innovations

SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

2

About the SSi Mantra

The SSi Mantra Surgical Robotic System is a u

EX-99.1

2 ea023628401ex99-1_ssinno.htm

PRESS RELEASE, DATED MARCH 31, 2025

Exhibit 99.1

SS Innovations Achieves Significant Milestones in 2024

The Company’s award winning SSi Mantra surgical robotic system has completed over 3,500 surgeries and is clinically validated to perform more than 100 different types of surgical procedures

The Company Continues to Build a Strong Foundation for Future Growth

FORT LAUDERDALE, FL, March 31, 2025 -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today provided shareholders and the investment community with a review of the significant milestones the Company achieved in 2024.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, and a pioneer in robotic cardiothoracic surgery, stated, “SS Innovations has built a strong foundation in 2024, laying the groundwork to achieve significant milestones in the years ahead.

“Looking ahead, we’re diligently working to secure regulatory approvals in the United States and Europe, which we expect to receive by the end of 2025 or early 2026. All of these initiatives have strengthened our foundation for future growth and our momentum is clearly building. We are excited to be progressing forward in fulfilling our mission to make robotic surgery accessible to the large global population in need of safe and affordable surgical services,” concluded Dr. Srivastava.

Operational Highlights

●We have now reached significant milestones of having 80 of our SSi Mantra Robotic Surgical Systems installed in 75 hospitals, performed over 3,500 surgeries using the SSi Mantra, including over 195 robotic cardiac surgeries, and the SSi Mantra has been validated in over 100 different surgical procedures.

●We are proud to report that in all our surgical robotic procedures we have reported zero device-related mortality, injuries, or complications.

●During the year ended December 31, 2024, we sold 37 of our SSi Mantra Surgical Robotic Systems and installed another 8 systems on a Pay-Per-Use Lease model. At the end of December 2024, we had 64 installations. We expect to report revenues of just over US$22 million for 2024 (based on preliminary unaudited results which are subject to change), an almost four-fold increase over our 2023 revenues. Our gross margins also continue to improve, from 12.30% in 2023 to an estimated 36.90% in 2024. We expect these margins to continue to increase as we achieve economies of scale, among other efficiencies.

●For the quarter ended March 31, 2025, we anticipate increasing the number of installations of our SSi Mantra Surgical Robotic Systems from 64 to 78 and estimate revenues for the quarter of approximately US$6.4 million (based on preliminary unaudited results which are subject to change), with a gross margin of approximately 45%.

●During 2024, we continued to grow and solidify our worldwide intellectual property portfolio, with 69 patent applications filed, 5 utility patents granted, and 30 design patents granted. We also have 53 registered trademarks.

●We also continue to expand our Board of Directors with the additions of independent Directors Tim Adams, Regional Operating Officer of Ascension and formerly regional CEO of Tenet Healthcare, and Dr. Frederic Moll, founder of Intuitive Surgical, joining as Vice Chairman.

●We have continued to increase our manufacturing and Research & Development capabilities, with a current capacity of producing 20 units per month, expandable to 35.

●We have now trained over 750 surgeons and over 1,000 surgical staff to use our SSi Mantra Surgical Robotic System.

●We have received Quality and Regulatory approvals in India, Nepal, Ecuador, Guatemala, Philippines, Indonesia, Ukraine and expect to quickly add more countries to this list.

●We have continued with our FDA and CE approvals and will provide periodic updates as the regulatory process proceeds. We expect to receive approvals for multiple indications by the end of 2025 or early 2026.

●In April 2024, we announced our first successful tele-surgery trials. Since then, we became the first and only company in India to receive Central Drugs Standard Control Organization (CDSCO, India’s equivalent of the U.S. FDA) regulatory approval for use of a robotic surgical system in the performance of Telesurgery and Tele-proctoring procedures. Since receiving such approvals, we have performed 16 telesurgeries using our SSi Mantra as of the date of this release, including a robotic cardiac surgery over a distance of 2,000km.

●In April 2024 we also announced the successful performance of the first pyeloplasty procedure performed on an infant utilizing our SSi Mantra Surgical Robotic System. The procedure was successfully completed on a 12-month-old baby weighing 8.5 kilograms (approximately 17.6 pounds). We have since used